Indivior Q3 2025 slides: SUBLOCADE drives growth, guidance raised amid restructuring
PositiveFinancial Markets

Indivior has reported strong growth in Q3 2025, primarily driven by the success of its product Sublocade. The company has raised its guidance for the year, reflecting confidence in its restructuring efforts and the ongoing demand for its treatments. This positive momentum is significant as it highlights Indivior's ability to adapt and thrive in a competitive market, ensuring better access to essential medications for patients.
— Curated by the World Pulse Now AI Editorial System










